TELIX PHARMACEUTICALS LTDTLX
ASignal's systematic analysis rates TLX as Neutral.
Reflects the latest available analysis · analyzed Sep 17, 2026
The case on TLX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Positive MACD histogram indicating strengthening momentum
- Price above 20-day and 50-day moving averages (bullish trend)
- Strong revenue growth year-over-year (22.3%)
- High growth score (0.9) reflecting expansion potential
- Current ratio above 2.0 indicating solid short-term financial health
- Negative free cash flow (-$62.60M)
- Negative operating cash flow (-$12.01M)
- High P/E and forward P/E ratios (131.44x, 211.05x) suggesting overvaluation
- Elevated debt-to-equity ratio (1.19x)
- No Reddit mentions indicating lack of retail investor interest
See the full verdict on TLX
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes TLX
Most investors never get a second opinion, let alone several. ASignal runs TLX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.